Atossa Genetics (ATOS) Trading Down 6.3%

Atossa Genetics Inc (NASDAQ:ATOS)’s share price dropped 6.3% on Friday . The stock traded as low as $1.33 and last traded at $1.34. Approximately 5,783 shares were traded during trading, a decline of 99% from the average daily volume of 1,031,420 shares. The stock had previously closed at $1.43.

Separately, Maxim Group reiterated a “buy” rating and set a $5.00 target price on shares of Atossa Genetics in a research report on Wednesday.

Atossa Genetics (NASDAQ:ATOS) last announced its quarterly earnings results on Tuesday, November 13th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.01. As a group, analysts anticipate that Atossa Genetics Inc will post -4.31 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This news story was originally posted by WKRB News and is the property of of WKRB News. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at

Atossa Genetics Company Profile (NASDAQ:ATOS)

Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions.

Further Reading: Certificate of Deposit (CD) For Risk Adverse Investors?

Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with's FREE daily email newsletter.

Leave a Reply